Literature DB >> 16901376

Treatment of sleep dysfunction and psychiatric disorders.

Philip M Becker1.   

Abstract

Patients with neurologic disorders commonly experience sleep dysfunction and psychiatric disorders. The most common sleep dysfunction is insomnia, which is a primary symptom in 30% to 90% of psychiatric disorders. Insomnia and fatigue are prominent symptoms of anxiety disorders and major depression, including patients who are treated but have residual symptoms. Anxiety and depressive disorders account for 40% to 50% of all cases of chronic insomnia. It is also recognized that primary insomnia and other primary sleep disorders produce symptoms that are similar to those reported by patients with psychiatric disorders. A clinician must judge whether sleep deprivation causes mood disturbance or whether depressive or anxiety disorder represents the primary reason for sleep dysfunction. When insomnia is comorbid with mild to moderate depression, therapy should begin with bedtime dosing of sedating antidepressants such as mirtazapine, nefazodone, or tricyclic antidepressants, which are preferred because of their sedative effects, although side effects may limit their usefulness. Intervention for chronic insomnia is similar in nonpsychiatric and psychiatric patients. Behavioral therapies, particularly cognitive behavioral therapy, and lifestyle changes show significant long-term efficacy as treatments for chronic insomnia. Sedative hypnotic agents are the most studied agents to treat insomnia, particularly those that are active through the benzodiazepine receptor-GABA complex, such as benzodiazepines, eszopiclone, zaleplon, and zolpidem. The new melatonin-receptor agonist ramelteon has not yet been studied in psychiatric patients. Prescription of adjunctive trazodone 50 to 150 mg is a common clinical practice to treat comorbid insomnia during antidepressant therapy, but published data are surprisingly limited when considered against the frequent usage of trazodone. Although there has been insufficient research on the use of atypical antipsychotic agents in severe insomnia, psychiatrists use quetiapine, olanzapine, or other agents to lessen agitation that disrupts sleep onset or maintenance. When insomnia or hypersomnia continues even as mood, anxiety, or thought disorders improve with standard therapy, the physician should consider the potential presence of underlying sleep disorders.

Entities:  

Year:  2006        PMID: 16901376     DOI: 10.1007/s11940-006-0026-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  34 in total

1.  Residual symptoms in depressed patients who respond acutely to fluoxetine.

Authors:  A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

2.  National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005.

Authors: 
Journal:  Sleep       Date:  2005-09       Impact factor: 5.849

Review 3.  A review of the evidence for the efficacy and safety of trazodone in insomnia.

Authors:  Wallace B Mendelson
Journal:  J Clin Psychiatry       Date:  2005-04       Impact factor: 4.384

Review 4.  Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults.

Authors:  Colin A Espie
Journal:  Annu Rev Psychol       Date:  2002       Impact factor: 24.137

Review 5.  Sleep and stroke.

Authors:  Claudio L Bassetti
Journal:  Semin Neurol       Date:  2005-03       Impact factor: 3.420

6.  Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.

Authors:  N Breslau; T Roth; L Rosenthal; P Andreski
Journal:  Biol Psychiatry       Date:  1996-03-15       Impact factor: 13.382

7.  Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia.

Authors:  Michael L Perlis; W Vaughn McCall; Andrew D Krystal; James K Walsh
Journal:  J Clin Psychiatry       Date:  2004-08       Impact factor: 4.384

8.  Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.

Authors:  Andrew D Krystal; James K Walsh; Eugene Laska; Judy Caron; David A Amato; Thomas C Wessel; Thomas Roth
Journal:  Sleep       Date:  2003-11-01       Impact factor: 5.849

Review 9.  Treatment of primary insomnia.

Authors:  Erika N Ringdahl; Susan L Pereira; John E Delzell
Journal:  J Am Board Fam Pract       Date:  2004 May-Jun

Review 10.  Treatment of insomnia associated with clinical depression.

Authors:  Ripu D Jindal; Michael E Thase
Journal:  Sleep Med Rev       Date:  2004-02       Impact factor: 11.609

View more
  11 in total

Review 1.  The complex role of sleep in adolescent depression.

Authors:  Greg Clarke; Allison G Harvey
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2012-04

Review 2.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

3.  Cognitive-behavioral treatment of insomnia and depression in adolescents: A pilot randomized trial.

Authors:  Greg Clarke; Eleanor L McGlinchey; Kerrie Hein; Christina M Gullion; John F Dickerson; Michael C Leo; Allison G Harvey
Journal:  Behav Res Ther       Date:  2015-04-14

4.  Sex Differences in Subjective Sleep Quality Patterns in Schizophrenia.

Authors:  Michelle H Chen; Stephanie A Korenic; Emerson M Wickwire; S Andrea Wijtenburg; L Elliot Hong; Laura M Rowland
Journal:  Behav Sleep Med       Date:  2019-08-28       Impact factor: 2.964

5.  Innovations in Practice: The relationship betweensleep disturbances, depression, and interpersonal functioning in treatment for adolescent depression.

Authors:  Eleanor L McGlinchey; Jazmin A Reyes-Portillo; J Blake Turner; Laura Mufson
Journal:  Child Adolesc Ment Health       Date:  2016-06-30       Impact factor: 2.175

6.  Patients with treatment-resistant insomnia taking nightly prescription medications for sleep: a retrospective assessment of diagnostic and treatment variables.

Authors:  Barry Krakow; Victor A Ulibarri; Edward A Romero
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

7.  Evaluation of trazodone and quetiapine for insomnia: an observational study in psychiatric inpatients.

Authors:  Shadi Doroudgar; Tony I-Fan Chou; Junhua Yu; Karen Trinh; Jai Pal; Paul J Perry
Journal:  Prim Care Companion CNS Disord       Date:  2013-11-07

8.  Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients.

Authors:  Marshall E Cates; Cherry W Jackson; Jacqueline M Feldman; Amanda E Stimmel; Thomas W Woolley
Journal:  Community Ment Health J       Date:  2009-05-27

9.  Antidepressants for the treatment of insomnia : a suitable approach?

Authors:  Michael H Wiegand
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine.

Authors:  P Feng; D Vurbic; Z Wu; Y Hu; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-09       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.